AI assistant
Sending…
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2019
Nov 8, 2019
31071_dirs_2019-11-07_012bb8ae-df66-48a3-9f6a-12094dd3ac3b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2019-11-05
Reporting Person: Myszkowski Kenneth Allen (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-11-05 | Common Stock | M | 12649 | $5.19 | Acquired | 326185 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-11-05 | Stock Option (right to buy) | $5.19 | M | 12649 | Disposed | 2022-02-16 | Common Stock (12649) | Direct |
Footnotes
F1: Represents first vesting date. Option vested over four years from date of grant.
More from ARROWHEAD PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 7
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Major Shareholding Notification
2026
Apr 28
Major Shareholding Notification
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 20
Interim / Quarterly Report
2026
Feb 5